Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
Avant Technologies (OTCQB: AVAI) has formed a strategic Joint Venture with Art-Islets and Austrianova to develop innovative diabetes treatments using encapsulated stem cells. The collaboration combines Art-Islets' stem cell differentiation expertise with Austrianova's cell-encapsulation technology to create therapies for type 1 and insulin-dependent type 2 diabetes patients.
The partnership includes exclusive licensing agreements and plans for a potential U.S.-based entity to support clinical trials. Avant will provide initial funding over eight months to achieve the first three milestones, with additional funding planned to advance toward Phase 1 clinical trials. Art-Islets contributes its proprietary differentiation system for transforming ESCs into insulin-producing cells, while Austrianova brings its GMP-grade manufacturing expertise backed by over 50 peer-reviewed publications.
Avant Technologies (OTCQB: AVAI) ha formato una joint venture strategica con Art-Islets e Austrianova per sviluppare trattamenti innovativi per il diabete basati su cellule staminali encapsulate. La collaborazione combina l'esperienza di Art-Islets nella differenziazione delle cellule staminali con la tecnologia di incapsulamento cellulare di Austrianova per creare terapie destinate a pazienti con diabete di tipo 1 e diabete di tipo 2 insulinodipendente.
La partnership prevede accordi di licenza esclusivi e piani per una possibile entità con sede negli Stati Uniti per supportare i trial clinici. Avant fornirà un finanziamento iniziale nell'arco di otto mesi per raggiungere i primi tre traguardi, con ulteriori fondi previsti per avanzare verso i trials di Fase 1. Art-Islets mette a disposizione il proprio sistema di differenziazione proprietario per trasformare le ESC in cellule produttrici di insulina, mentre Austrianova apporta la sua esperienza di produzione GMP supportata da oltre 50 pubblicazioni peer-reviewed.
Avant Technologies (OTCQB: AVAI) ha formado una empresa conjunta estratégica con Art-Islets y Austrianova para desarrollar tratamientos innovadores para la diabetes utilizando células madre encapsuladas. La colaboración combina la experiencia de diferenciación de células madre de Art-Islets con la tecnología de encapsulación de células de Austrianova para crear terapias para pacientes con diabetes tipo 1 y diabetes tipo 2 insulinodependiente.
La asociación incluye acuerdos de licencia exclusivos y planes para una posible entidad con sede en Estados Unidos para apoyar los ensayos clínicos. Avant proporcionará financiación inicial durante ocho meses para lograr los primeros tres hitos, con financiación adicional prevista para avanzar hacia ensayos clínicos de Fase 1. Art-Islets aporta su sistema de diferenciación propietario para transformar ESCs en células productoras de insulina, mientras que Austrianova aporta su experiencia de fabricación GMP respaldada por más de 50 publicaciones revisadas por pares.
Avant Technologies (OTCQB: AVAI)는 Art-Islets 및 Austrianova와 함께 캡슐화된 줄기세포를 활용한 혁신적인 당뇨병 치료를 개발하기 위한 전략적 공동 벤처를 설립했습니다. 이 협력은 Art-Islets의 줄기세포 분화 전문지식과 Austrianova의 세포 캡슐화 기술을 결합하여 제1형 당뇨병과 인슐린 의존형 제2형 당뇨병 환자를 위한 치료법을 창출합니다.
파트너십은 독점 라이선스 계약과 임상시험을 지원하기 위한 미국 기반의 법인 설립 가능성에 대한 계획을 포함합니다. Avant가 초기 자금을 8개월 동안 제공하여 최초의 세 가지 이정표를 달성하고, 1상 임상시험으로의 진전을 위한 추가 자금을 계획합니다. Art-Islets는 인슐린 생산 세포로 ESC를 변환하는 독점 분화 시스템을 제공하고, Austrianova는 50편이 넘는 동료평가 논문으로 뒷받침되는 GMP 등급 제조 역량을 제공합니다.
Avant Technologies (OTCQB: AVAI) a formé une coentreprise stratégique avec Art-Islets et Austrianova pour développer des traitements innovants du diabète utilisant des cellules souches encapsulées. La collaboration combine l'expertise d'Art-Islets en matière de différenciation des cellules souches avec la technologie d'encapsulation cellulaire d'Austrianova afin de créer des thérapies pour les patients atteints de diabète de type 1 et de diabète de type 2 insulinodépendant.
Le partenariat comprend des accords de licence exclusifs et des plans pour une entité potentielle basée aux États‑Unis afin de soutenir les essais cliniques. Avant fournira un financement initial sur une période de huit mois pour atteindre les trois premiers jalons, avec des financements supplémentaires prévus pour progresser vers des essais cliniques de phase 1. Art-Islets apporte son système de différenciation propriétaire pour transformer des ESC en cellules productrices d'insuline, tandis qu'Austrianova apporte son savoir-faire de fabrication conforme aux BPF, étayé par plus de 50 publications évaluées par des pairs.
Avant Technologies (OTCQB: AVAI) hat eine strategische Joint Venture mit Art-Islets und Austrianova zur Entwicklung innovativer Diabetes-Behandlungen mit eingeschlossenen Stammzellen gebildet. Die Zusammenarbeit kombiniert Art-Islets' Fachwissen in der Stammzellendifferenzierung mit Austrianovas Zellencapsulation-Technologie, um Therapien für Patienten mit Typ-1-Diabetes und insulinabhängigem Typ-2-Diabetes zu entwickeln.
Die Partnerschaft umfasst exklusive Lizenzvereinbarungen und Pläne für eine potenzielle in den USA ansässige Einheit zur Unterstützung klinischer Studien. Avant wird in acht Monaten eine erste Finanzierung bereitstellen, um die ersten drei Meilensteine zu erreichen, und weitere Mittel sind vorgesehen, um Fortschritte in Richtung klinischer Phase-1-Studien zu ermöglichen. Art-Islets trägt sein proprietäres Differenzierungssystem zur Umwandlung von ESCs in insulinproduzierende Zellen bei, während Austrianova seine GMP-konforme Herstellungsfähigkeit mit Unterstützung von über 50 peer-reviewed Publikationen einbringt.
Avant Technologies (OTCQB: AVAI) أُنشئت شراكة استراتيجية مع Art-Islets وAustrianova لتطوير علاجات مبتكرة لمرض السكري باستخدام الخلايا الجذعية المحاطة. تجمع الشراكة بين خبرة Art-Islets في تمييز الخلايا الجذعية وتكنولوجيا تغليف الخلايا الخاصة بـ Austrianova لإنتاج علاجات موجهة لمرضى السكري من النوع 1 ومرضى النوع 2 المعتمدين على الأنسولين.
تشمل الشراكة اتفاقيات ترخيص حصرية وخطط لإنشاء كيان مقره في الولايات المتحدة لدعم التجارب السريرية. ستقدم Avant تمويلاً أولياً خلال ثمانية أشهر لتحقيق أول ثلاث مراحل رئيسية، مع وجود تمويل إضافي مخطط له للمضي قدماً نحو تجارب المرحلة 1. تساهم Art-Islets بنظام تفاضل مملوك يحوِّل الخلايا الجذعية إلى خلايا منتجة للأنسولين، بينما تقدم Austrianova خبرتها في التصنيع وفقاً لمعايير GMP مدعومة بأكثر من 50 منشوراً مُراجَعاً من نظرائها.
Avant Technologies (OTCQB: AVAI) 已与 Art-Islets 和 Austrianova 形成战略性合资企业，利用包裹化干细胞开发创新的糖尿病治疗方法。此次合作将 Art-Islets 的干细胞分化专业知识与 Austrianova 的细胞包裹技术结合起来，旨在为1型糖尿病和需要胰岛素的2型糖尿病患者开发治疗方案。
该伙伴关系包括独家许可协议，并计划设立在美国的潜在实体以支持临床试验。Avant 将在八个月内提供初始资金以实现前3个里程碑，并计划追加资金以推进进入1期临床试验。Art-Islets 提供其专有的分化系统，将 ESC 转化为产生胰岛素的细胞，而 Austrianova 则带来其 GMP 级制造经验，并有超过50篇同行评审出版物的支持。
- Formation of strategic Joint Venture combining complementary biotechnology expertise in diabetes treatment
- Exclusive licensing agreements secured for proprietary stem cell and encapsulation technologies
- Potential establishment of U.S.-based entity for clinical trials
- Austrianova brings proven expertise with over 50 peer-reviewed publications and contracts with leading pharma companies
- Initial funding timeline limited to eight months for first three milestones
- Additional funding requirements needed for advancing to Phase 1 clinical trials
- Early-stage development with no immediate revenue potential
- Clinical trial success and regulatory approval uncertainties
This strategic collaboration is dedicated to researching, developing, manufacturing, and commercializing advanced treatments for diabetes using encapsulated stem cells differentiated before, during, or after encapsulation. By combining Art-Islets' stem cell differentiation expertise with Austrianova's encapsulation technology, the partnership aims to create safe, effective, and scalable therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide.
The collaboration may lead to the establishment of a new
Avant's Chief Executive Officer (CEO), Chris Winter, said of the collaboration, "We are incredibly excited to partner with Art-Islets and Austrianova in this transformative Joint Venture. By combining our financial resources and strategic vision with their cutting-edge biotechnologies, we are paving the way for groundbreaking diabetes treatments that could change millions of lives. This agreement marks a pivotal moment for Avant as we invest in the future of regenerative medicine."
Key Contributions to the Joint Venture:
- Art-Islets contributes its proprietary "differentiation system," enabling the highefficiency transformation of ESCs into insulin-producing and regulating cells. This technology will be exclusively licensed to the Joint Venture for developing diabetes treatments.
- Austrianova brings its proprietary cell-encapsulation technology, designed to protect, isolate, store, and transport living cells to the Joint Venture. Backed by over 50 peerreviewed publications and contracts with leading global pharmaceutical and biotechnology companies, Austrianova's expertise in cell biology and GMP-grade manufacturing will support the development and commercialization of these treatments.
- Avant Technologies will provide initial funding over the next eight months to achieve the first three (3) milestones outlined in the agreement. Additionally, Avant will leverage its resources to secure further funding to advance the Joint Venture toward a potential Phase 1 clinical trial in
the United States or equivalent territory.
"Austrianova's cell encapsulation technology has immense potential to revolutionize cell-based therapies, and this Joint Venture is a testament to that promise," said Brian Salmons, CEO of Austrianova. "By collaborating with Avant and Art-Islets, we are harnessing our collective strengths to develop innovative, high-quality solutions for diabetes management, backed by our proven expertise in GMP manufacturing and cell biology."
The CEO of Art-Islets, Kristmundur Sigmundsson, added, "At Art-Islets, our proprietary stem cell differentiation technology represents years of dedicated research to address the global diabetes challenge. This joint venture allows us to bring our innovation to the next level, combining our expertise with world-class encapsulation technology to deliver safe and effective therapies for patients worldwide."
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging
About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in
Art-Islets Pte. Ltd.
Art-Islets is a Singaporean biotech company specializing in stem cell differentiation for insulinproducing cells, Art-Islets is at the forefront of regenerative medicine.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Logo: https://mma.prnewswire.com/media/2370694/5517509/Avant_Technologies.jpg
View original content:https://www.prnewswire.com/news-releases/avant-technologies-art-islets-and-austrianova-announce-joint-venture-to-advance-diabetes-treatment-302565832.html
SOURCE Avant Technologies Inc.
FAQ
What is the purpose of the Joint Venture between Avant Technologies (AVAI), Art-Islets, and Austrianova?
What technologies are being contributed to the AVAI Joint Venture?
What is Avant Technologies' (AVAI) role in the diabetes treatment Joint Venture?
How will the AVAI Joint Venture advance its diabetes treatment development?
What is the current development stage of AVAI's diabetes treatment program?
